The creatine kinase/creatine connection to Alzheimer's disease:: CK inactivation, APP-CK complexes, and focal creatine deposits

被引:83
作者
Burklen, Tanja S. [1 ]
Schlattner, Uwe
Homayouni, Ramin
Gough, Kathleen
Rak, Margaret
Szeghalmi, Adriana
Wallimann, Theo
机构
[1] ETH, Honggerberg HPN, Inst Cell Biol, CH-8093 Zurich, Switzerland
[2] Univ Grenoble 1, INSERM, E0221, Lab Fundamental & Appl Bioenerget, F-38041 Grenoble 9, France
[3] Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA
[4] Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada
来源
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2006年
关键词
D O I
10.1155/JBB/2006/35936
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cytosolic brain-type creatine kinase (BB-CK), which is coexpressed with ubiquitous mitochondrial uMtCK, is significantly inactivated by oxidation in Alzheimer's disease (AD) patients. Since CK has been shown to play a fundamental role in cellular energetics of the brain, any disturbance of this enzyme may exasperate the AD disease process. Mutations in amyloid precursor protein (APP) are associated with early onset AD and result in abnormal processing of APP, and accumulation of A beta peptide, the main constituent of amyloid plaques in AD brain. Recent data on a direct interaction between APP and the precursor of uMtCK support an emerging relationship between AD, cellular energy levels, and mitochondrial function. In addition, recently discovered creatine (Cr) deposits in the brain of transgenic AD mice, as well as in the hippocampus from AD patients, indicate a direct link between perturbed energy state, Cr metabolism, and AD. Here, we review the roles of Cr and Cr-related enzymes and consider the potential value of supplementation with Cr, a potent neuroprotective substance. As a hypothesis, we consider whether Cr, if given at an early time point of the disease, may prevent or delay the course of AD-related neurodegeneration.
引用
收藏
页数:11
相关论文
共 134 条
[91]   Control of glutamate clearance and synaptic efficacy by glial coverage of neurons [J].
Oliet, SHR ;
Piet, R ;
Poulain, DA .
SCIENCE, 2001, 292 (5518) :923-926
[92]  
PARKER WD, 1991, ANN NY ACAD SCI, V640, P59
[93]   Neurochemical correlates of differential neuroprotection by long-term dietary creatine supplementation [J].
Peña-Altamira, E ;
Crochemore, C ;
Virgili, M ;
Contestabile, A .
BRAIN RESEARCH, 2005, 1058 (1-2) :183-188
[94]   Alzheimer's Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies [J].
Pereira, C. ;
Agostinho, P. ;
Moreira, P., I ;
Cardoso, S. M. ;
Oliveira, C. R. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (04) :383-403
[95]   ALTERATIONS OF CEREBRAL METABOLISM IN PROBABLE ALZHEIMERS-DISEASE - A PRELIMINARY-STUDY [J].
PETTEGREW, JW ;
PANCHALINGAM, K ;
KLUNK, WE ;
MCCLURE, RJ ;
MUENZ, LR .
NEUROBIOLOGY OF AGING, 1994, 15 (01) :117-132
[96]   Creatine diet supplement for spinal cord injury: Influences on functional recovery and tissue sparing in rats [J].
Rabchevsky, AG ;
Sullivan, PG ;
Fugaccia, I ;
Scheff, SW .
JOURNAL OF NEUROTRAUMA, 2003, 20 (07) :659-669
[97]   Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial [J].
Rae, C ;
Digney, AL ;
McEwan, SR ;
Bates, TC .
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2003, 270 (1529) :2147-2150
[98]  
ROSSI AM, 1990, J BIOL CHEM, V265, P5258
[99]   Cardiac system bioenergetics: metabolic basis of the Frank-Starling law [J].
Saks, V ;
Dzeja, P ;
Schlattner, U ;
Vendelin, M ;
Terzic, A ;
Wallimann, T .
JOURNAL OF PHYSIOLOGY-LONDON, 2006, 571 (02) :253-273
[100]  
Saks V A, 1992, Biokhimiia, V57, P1763